Clinical

Dataset Information

0

Phase I trial of combined chemotherapy of bevacizumab, panitumumab and irinotecan as 3rd-line chemotherapy in chmotherapy-refractory metastatic colorectal cancer.


ABSTRACT: Interventions: Combined chemotherapy of bevacizumab, panitumumab, irinotecan. Primary outcome(s): Proportion of dose limiting toxicity (DLT). Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2624760 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2520710 | ecrin-mdr-crc
2015-11-11 | GSE66999 | GEO
| 2075260 | ecrin-mdr-crc
2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress
| 2620326 | ecrin-mdr-crc
2019-01-23 | GSE102995 | GEO
| 2635158 | ecrin-mdr-crc
| 2063458 | ecrin-mdr-crc
| S-EPMC3231982 | biostudies-literature
2024-01-27 | GSE254054 | GEO